Stock Price Quote

AMBALAL SARABHAI ENTERPRISES LTD.

NSE : AMBALALSABSE : 500009ISIN CODE : INE432A01017Industry : Pharmaceuticals & DrugsHouse : Sarabhai
BSE42.471.19 (+2.88 %)
PREV CLOSE ( ) 41.28
OPEN PRICE ( ) 41.01
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 31065
TODAY'S LOW / HIGH ( )41.01 43.55
52 WK LOW / HIGH ( )23.12 49.85
NSE42.270.73 (+1.76 %)
PREV CLOSE( ) 41.54
OPEN PRICE ( ) 41.30
BID PRICE (QTY) 42.27 (150)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 206876
TODAY'S LOW / HIGH( ) 41.30 43.49
52 WK LOW / HIGH ( )30.15 49.98
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 05-06 1978
Management Info
Kartikeya V Sarabhai - Chairman Mohal K Sarabhai - Managing Director
Registered Office

Address Shanti Sadan ,Mirzapur Road , ,
Ahmedabad,
Gujarat-380001

Phone 079-25507671 / 25507073

Email ase@sarabhai.co.in

Website www.ase.life

Registrars Details
MCS Ltd
3B3 3rd Floor,Gundecha Onclave,Kherani Road Sakinaka Andheri (E),Mumbai
Listing : BSE, NSE

NEWS

06Aug Clarification On Price Movement
We here by submit a Clarification on Price Movement. Kindly take the..
05Aug Clarification Sought from Ambalal Sar
The Exchange has sought clarification from Ambalal Sarabhai Enterprises..
31Jul Ambalal Sarabhai Enterprises submits v
Pursuant to Regulation 44(3) of the SEBI (Listing Obligations and Disclo..
13Jul Ambalal Sarabhai Enterprises informs a
Ambalal Sarabhai Enterprises has informed that it enclosed copies of new..
07Jul Ambalal Sarabhai Enterprises informs a
Ambalal Sarabhai Enterprises has informed that he 48th Annual General Me..

Financials

in Millions
QTR Jun 26 ANNUAL 26
Net Profit0.31109.91
Gross Profit 2.87 99.5
Operating Profit 4.77104.49
Net Sales 5.4439.44

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Kwality Pharma (BSE)
peergroup  3444.75 (3.53%)
M.Cap ( in Cr)3574.34
Neuland Laboratories (BSE)
peergroup  23311.50 (0.38%)
M.Cap ( in Cr)29908.40
Ajanta Pharma (BSE)
peergroup  3675.15 (1.64%)
M.Cap ( in Cr)45924.32
Fredun Pharma (BSE)
peergroup  1547.75 (3.33%)
M.Cap ( in Cr)2559.68
Venus Remedies (BSE)
peergroup  1786.80 (2.86%)
M.Cap ( in Cr)2388.41

Shareholding Pattern

NON-INSTITUTION 68.64%
PROMOTERS 31.36%
FI/BANKS/INSURANCE 0%
MUTUAL FUNDS/UTI 0%
GOVERNMENT 0%
FII 0%

About Ambalal Sarabhai Enterprises Ltd.

Ambalal Sarabhai Enterprises Ltd. was incorporated in the year 1978. Its today's share price is 42.47. Its current market capitalisation stands at Rs 325.46 Cr. In the latest quarter, company has reported Gross Sales of Rs. 39.44 Cr and Total Income of Rs.195.17 Cr. The company's management includes Bharatendu Jani, Ajay Mayor, Satyen Dave, Pushpa Robin, Mayur Swadia, Govindprasad Namdeo, Brijesh Khandelwal, Chaula Shastri, Mohal K Sarabhai, Kartikeya V Sarabhai, Disha Mahesh Punjani.

It is listed on the BSE with a BSE Code of 500009 , NSE with an NSE Symbol of AMBALALSA and ISIN of INE432A01017. It's Registered office is at Shanti Sadan ,Mirzapur Road , Ahmedabad-380001, Gujarat. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Khandhar & Associates, Sorab S Engineer & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.